This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Paramithiotis, E. et al. Nat. Med. 9, 893–899 (2003).
Korth, C. et al. Nature 390, 74–77 (1997).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
This response letter represents an ongoing University-Industry collaboration between scientists at the University of Toronto and two biotechnology companies (Caprion Pharmaceuticals of Montreal, Canada, and Idexx Laboratories of Portland, Maine). N.R.C., the senior author, is a professor at the University of Toronto, as well as 'Founder and Scientific Advisor' of Caprion Pharmaceuticals, from which he has derived partial salary and laboratory operating grants. The commercial aspects of this discovery are being developed under license from Caprion to Idexx and Ortho Clinical Diagnostics.
Rights and permissions
About this article
Cite this article
Paramithiotis, E., Pinard, M., Lawton, T. et al. Reply to “Properties of a disease-specific prion probe”. Nat Med 10, 11–12 (2004). https://doi.org/10.1038/nm0104-11b
Issue Date:
DOI: https://doi.org/10.1038/nm0104-11b